Preliminary Moderna data indicates COVID-19 vaccine effective against variants
Coronavirus update for NYC
Moderna on Tuesday released preliminary data indicating its vaccine is likely to hold up against several variants of concern, including the Delta variant, which is predicted to become the dominant variant in the United States.
The data, which has not yet been peer reviewed, is preliminary but promising.
In the experiments, scientists took blood samples from people who have already been vaccinated and tested it against variants in a laboratory. This type of experiment can offer a rough sense of whether the vaccine will work against a new variant.
RELATED | Delta variant: What New Yorkers need to know
The Moderna vaccine appeared to work against all variants, as indicated by so-called "neutralizing antibody titers."
Some of the variants -- including Delta (first identified in India), Beta (first identified in South Africa), and Gamma (first identified in Brazil) -- showed a slight reduction in these neutralizing antibody titers, but scientists say these slight reductions aren't enough to evade the vaccine.
This type of experiment does not indicate an exact percentage of exactly how effective Moderna's vaccine is likely to be against each variant.
A prior real-world study from the United Kingdom indicated the Pfizer vaccine, which uses a similar mRNA technology, was 88% effective against the Delta variant in terms of protecting people from symptomatic disease.
ALSO READ | Curtain lifts on first full-capacity Broadway show since pandemic began
Taken collectively, these studies are encouraging news that mRNA vaccines are holding up against the Delta variant.
MORE CORONAVIRUS COVID-19 COVERAGE
Mask guidance in the Tri-State area
New York City COVID-19 Vaccine Tracker
New Jersey COVID-19 Vaccine Tracker
How to get the vaccine in NYC, Tri-State area
Centers for Disease Control and Prevention on coronavirus
Submit a News Tip or Question
